Business
Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency
Data presented at the American Epilepsy Society Annual Meeting TSHA-105 normalized electroencephalogram (EEG) and citrate levels and improved survival in
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nData presented at the American Epilepsy Society Annual Meeting\n\nTSHA-105 normalized electroencephalogram (EEG) and citrate levels and improved survival in both early treated juvenile and later treated adult preclinical mouse models of SLC13A5 deficiency\n\nNo adverse findings detected following CSF delivery of TSHA-105\n\nTSHA-105 granted orphan drug designation from the U.S. FDA and the European Commission\n\nIND/CTA filing expected in 2022\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced a late-breaking abstract and poster presentation by Dr. Rachel Bailey, Assistant Professor at UT Southwestern Medical Center on positive preclinical data for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy at the American Epilepsy Society Annual Meeting on December 6th 2021.\n\n“SLC13A5-related epilepsy results from a mutation in the SLC13A5 gene that prevents citrate from being taken up into neurons in the brain. Affected children present with seizures beginning within a few days of birth and as they continue to grow, have motor progression and difficulty with speech and language development. Some children never achieve walking independently,” said Rachel M. Bailey, Ph.D., Assistant Professor with the Center for Alzheimer's and Neurodegenerative Diseases and Pediatrics at UT Southwestern. “Currently there are no treatments for SLC13A5 deficiency that target the underlying cause of disease. In knockout mouse models of SLC13A5 deficiency, treatment with TSHA-105 resulted in normalized citrate levels, reduced seizure activity and improved survival regardless of age. We are highly encouraged by the positive therapeutic response and absence of toxicity in these preclinical models and look forward to further exploring the possible utility of TSHA-105 as a treatment for SLC13A5 deficiency.”\n\nDr. Bailey, whose research is supported in part by Taysha, and UT Southwestern maintain financial interests in Taysha Gene Therapies due to their development of the intellectual property that serves as the basis for TSHA-105.\n\n“These preclinica...